GF82117447
Bismuth
foil, not light tested, 50x50mm, thickness 0.001mm, permanent polyester support, 99.97%
Synonym(s):
Bismuth, BI000020
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
vapor pressure
<0.1 mmHg ( 20 °C)
Assay
99.97%
form
foil
manufacturer/tradename
Goodfellow 821-174-47
resistivity
129 μΩ-cm, 20°C
size × thickness
50 x 50 mm × 0.001 mm
bp
1560 °C (lit.)
mp
271 °C (lit.)
density
9.8 g/mL at 25 °C (lit.)
SMILES string
[Bi]
InChI
1S/Bi
InChI key
JCXGWMGPZLAOME-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
General description
For updated SDS information please visit www.goodfellow.com.
Legal Information
Product of Goodfellow
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Metallomics : integrated biometal science, 4(3), 239-243 (2012-02-24)
Helicobacter pylori causes various gastric diseases, such as gastritis, peptic ulcerations and gastric cancer. Bismuth-based triple or quadruple therapies have been commonly recommended for the treatment of H. pylori infections. Up to now, the molecular mechanisms by which bismuth inhibits
Syntheses of biodegradable and biocompatible polymers by means of bismuth catalysts.
Chemical reviews, 109(11), 5579-5594 (2009-09-26)
Future medicinal chemistry, 4(11), 1495-1523 (2012-08-04)
In recent years, the chemical potential of bismuth and bismuth compounds has been actively exploited. Bismuth salts are known for their low toxicity, making them potential valuable reagents for large-scale synthesis, which becomes more obvious when dealing with products such
Bismuth in medicine.
Metal ions in biological systems, 41, 333-378 (2004-06-23)
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 55(12), 2012-2019 (2014-10-29)
Nonuniform dose distributions among disseminated tumor cells can be a significant limiting factor in targeted α therapy. This study examines how cocktails of radiolabeled antibodies can be formulated to overcome this limitation. Cultured MDA-MB-231 human breast cancer cells were treated
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service